Neurobrucellosis:The Great Mimicker
Rev Soc Bras Med Trop 55:e0567-e2012, Soares,C.N.,et al, 2022
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Double-Blind Assessment of Potential Pergolide-Induced Cardiotoxicity
Neurol 36:993-995, Kurlan,R.,et al, 1986
Effect of Dopamine Agonist Withdrawal After Long-Term Therapy in Prolactinomas
Lancet 2:187-192, Johnston,D.G.,et al, 1984
Progressive Supranuclear Palsy:Clinical Features & Response to Treatment in 16 Patients
Ann Neurol 13:273-278, Jackson,J.A.,et al, 1983
Pergolide for the Treatment of Pituitary Tumors Secreting Prolactin or Growth Hormone
NEJM 309:704-709, Kleinberg,D.K.,et al, 1983
Reduction in Size of Prolactin-secreting Tumours in Men Treated with Pergolide
BMJ 285:465-467, Kendall-Taylor,P.,et al, 1982
Treatment of Advanced Parkinson Disease With Pergolide
Neurol 31:675-682, Lieberman,A.,et al, 1981